Compounds > kni-727
Page last updated: 2024-12-08

kni-727

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

KNI-727: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID451416
CHEMBL ID282457
SCHEMBL ID13788241
MeSH IDM0400183

Synonyms (15)

Synonym
(r)-n-tert-butyl-3-[(2s,3s)-3-(2,6-dimethylpropylphenoxyacetyl)amino-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
bdbm712
(4r)-n-tert-butyl-3-[(2s,3s)-3-[2-(2,6-dimethylphenoxy)acetamido]-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
je-1482
n-(3-{(4r)-4-[n-(tert-butyl)carbamoyl]-5,5-dimethyl(1,3-thiazolidin-3-yl)}(1s,2s)-2-hydroxy-3-oxo-1-benzylpropyl)-2-(2,6-dimethylphenoxy)acetamide
189357-33-3
(4r)-n-tert-butyl-3-[(2s,3s)-3-[[2-(2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy-4-phenyl-butanoyl]-5,5-dimethyl-thiazolidine-4-carboxamide
kni-727
thiazolidinecarboxamide, n-(1,1-dimethylethyl)-3-[(2s,3s)-3-[[(2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy-1-oxo-4-phenylbutyl]-5,5-dimethyl-, (4r)-
CHEMBL282457
kni 727
n-(3-((4r)-4-(n-(tert-butyl)carbamoyl)-5,5-dimethyl(1,3-thiazolidin-3-yl))(1s,2s)-2-hydroxy-3-oxo-1-benzylpropyl)-2-(2,6-dimethylphenoxy)acetamide
thiazolidinecarboxamide, n-(1,1-dimethylethyl)-3-((2s,3s)-3-(((2,6-dimethylphenoxy)acetyl)amino)-2-hydroxy-1-oxo-4-phenylbutyl)-5,5-dimethyl-, (4r)-
SCHEMBL13788241
DTXSID10172343

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The present study demonstrated that JE-2147 has potent antiviral activities in vitro and exhibits good oral bioavailability and plasma pharmacokinetic profiles in two species of laboratory animals."( Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
Fukazawa, T; Hayashi, H; Kato, R; Kiso, Y; Mimoto, T; Misawa, S; Nojima, S; Sato, H; Shintani, M; Takaku, H; Terashima, K; Ueno, T, 1999)		0.3
" A clear increase in the gastrointestinal absorption was observed in prodrugs 8, 12, and 13 with bioavailability (BA) values of 23%, 26%, and 29%, respectively."( Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.
Hayashi, Y; Ito, T; Kimura, T; Kiso, Y; Matsumoto, H; Sohma, Y, 2003)		0.55
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gag-Pol polyproteinHuman immunodeficiency virus type 1 (NEW YORK-5 ISOLATE)Ki0.00140.00000.12203.1000AID1795265
Protease Human immunodeficiency virus 1Ki0.00140.00000.04433.1000AID160444
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID442712Aqueous solubility in 0.1% TFA after 30 mins by RP-HPLC analysis2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.
AID442703Inhibition of HIV1 recombinant protease at 50 nM after 15 mins by fluorescence assay2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.
AID21989Water solubility of prodrug was determined2001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Controlled drug release: new water-soluble prodrugs of an HIV protease inhibitor.
AID442706Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay in absence of human serum2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.
AID1383896Antiviral activity against HIV1 Lai infected in human MOLT4 cells after 7 days by WST8 assay2018European journal of medicinal chemistry, Apr-25, Volume: 150Polypharmacology in HIV inhibition: can a drug with simultaneous action against two relevant targets be an alternative to combination therapy?
AID160635Relative potency of compound to that of parent HIV Protease inhibitor, KNI-727 was determined2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
'Double-Drugs'--a new class of prodrug form of an HIV protease inhibitor conjugated with a reverse transcriptase inhibitor by a spontaneously cleavable linker.
AID442710Ratio of EC50 for HIV1 3B infected in human MT4 cells in presence of 50% human serum to EC50 for HIV1 3B infected in human MT4 cells in absence of human serum2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.
AID21990Water solubility of prodrug was determined relative to KNI-7272001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Controlled drug release: new water-soluble prodrugs of an HIV protease inhibitor.
AID162673Compound was evaluated for the percentage inhibition of HIV protease at 5 uM2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
'Double-Drugs'--a new class of prodrug form of an HIV protease inhibitor conjugated with a reverse transcriptase inhibitor by a spontaneously cleavable linker.
AID29706T max was determined2003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.
AID23665C max was determined2003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.
AID162546Inhibition of recombinant HIV-1 protease (NY-5) using 50 nM1999Journal of medicinal chemistry, May-20, Volume: 42, Issue:10
Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
AID160444Inhibition of recombinant HIV-1 protease (NY-5)1999Journal of medicinal chemistry, May-20, Volume: 42, Issue:10
Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
AID25464Area under curve (AUC) was determined2003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.
AID21762Solubility2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Effect of the acyl groups on O-->N acyl migration in the water-soluble prodrugs of HIV-1 protease inhibitor.
AID20043Water solubility by RP-HPLC2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
'Double-Drugs'--a new class of prodrug form of an HIV protease inhibitor conjugated with a reverse transcriptase inhibitor by a spontaneously cleavable linker.
AID29462Bioavailability2003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.
AID46077Toxic concentration was determined for CEM-SS cells1999Journal of medicinal chemistry, May-20, Volume: 42, Issue:10
Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
AID162545Inhibition of recombinant HIV-1 protease (NY-5) using 5 uM1999Journal of medicinal chemistry, May-20, Volume: 42, Issue:10
Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
AID442708Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay in presence of 50% human serum2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.
AID125353Compound was evaluated for anti-HIV activity against HIV-1Lal inoculated with Molt-4 cells2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
'Double-Drugs'--a new class of prodrug form of an HIV protease inhibitor conjugated with a reverse transcriptase inhibitor by a spontaneously cleavable linker.
AID45886Antiviral activity was determined based on inhibition of HIV-1 IIIB induced cytopathic effects in CEM-SS cells in vitro using tetrazolium reagent.1999Journal of medicinal chemistry, May-20, Volume: 42, Issue:10
Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
AID1795265Protease Inhibition Assay from Article 10.1021/jm980637h: \\Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.\\1999Journal of medicinal chemistry, May-20, Volume: 42, Issue:10
Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (10.00)18.2507
2000's8 (80.00)29.6817
2010's1 (10.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.30 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.70 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.30)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
carbamates
[no description available]		2.0110amino-acid anion
alizarin
[no description available]		3.2710dihydroxyanthraquinonechromophore;
dye;
plant metabolite
thiazoles
[no description available]		2.93401,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		3.8230azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
adefovir
adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).. adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.		3.27106-aminopurines;
ether;
phosphonic acids		antiviral drug;
DNA synthesis inhibitor;
drug metabolite;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent
kynostatin 272
kynostatin 272: structure given in first source; contains allophenylnorstatine as a transition-state mimic		210peptide
kynostatin 227
kynostatin 227: structure given in first source; contains allophenylnorstatine as a transition-state mimic		210
lopinavir
[no description available]		2.0510amphetamines;
dicarboxylic acid diamide		anticoronaviral agent;
antiviral drug;
HIV protease inhibitor
3-amino-2-hydroxy-4-phenylbutanoic acid
[no description available]		2.0110
fosamprenavir
fosamprenavir: a prodrug of the protease inhibitor amprenavir. fosamprenavir : A sulfonamide with a structure based on that of sulfanilamide substituted on the sulfonamide nitrogen by a (2R,3S)-4-phenyl-2-(phosphonooxy)-3-({[(3S)-tetrahydrofuran-3-yloxy]carbonyl}amino)butyl group. It is a pro-drug of the HIV protease inhibitor and antiretroviral drug amprenavir.		2.0110sulfonamideprodrug
je 2147
[no description available]		2.4220
tenofovir
tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.		3.2710nucleoside analogue;
phosphonic acids		antiviral drug;
drug metabolite;
HIV-1 reverse transcriptase inhibitor
6-phosphonylmethoxyethoxy-2,4-diaminopyrimidine
[no description available]		3.2710
didanosine
Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.		3.2710purine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		03.0910